A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma

简要总结

主要结局

次要结局

• Objective Response Rate (ORR) According to PD-L1 Expression Level(From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months))
• Disease Control Rate (DCR)(From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months)
• Progression Free Survival (PFS)(From randomization date to the date of first documented tumor progression or death due to any cause, whichever occurs first. (up to 76 months))
• Overall Survival (OS) According to PD-L1 Expression Level(From randomization date to the date of death (Up to 76 Months))
• Progression Free Survival (PFS) According to PD-L1 Expression Level(From randomization date to the date of first documented tumor progression or death due to any cause, whichever occurs first. (up to 76 months))
• Objective Response Rate (ORR)(From randomization date to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (Up to 76 months))